SARS-CoV-2

There are new flu vaccines on offer for 2024. Should I get one? What do I need to know?

Retrieved on: 
Wednesday, April 3, 2024

Although most cases are relatively mild, flu can cause more severe illness in young children and older people.

Key Points: 
  • Although most cases are relatively mild, flu can cause more severe illness in young children and older people.
  • Influenza virtually disappeared from Australia during the first years of the COVID-19 pandemic when public health restrictions reduced contact between people.
  • Since 2022, it has returned to a seasonal pattern, although the flu season has started and peaked a few months earlier than before 2020.

What goes into a flu vaccine?

  • Influenza strains are constantly changing due to genetic mutation, with the pace of genetic change much higher than for SARS-CoV-2 (the virus that causes COVID).
  • Read more:
    Flu vaccine won't definitely stop you from getting the flu, but it's more important than you think

    All current influenza vaccines in Australia contain four different strains (known as quadrivalent vaccines).

What’s different about new flu vaccines?

  • These include egg-based vaccines (Vaxigrip Tetra, Fluarix Tetra, Afluria Quad, FluQuadri and Influvac Tetra), cell-based vaccines (Flucelvax Quad), adjuvanted vaccines (Fluad Quad) and high-dose vaccines (Fluzone High-Dose Quad).
  • Until recently, the process of manufacturing flu vaccines has remained similar.
  • In some flu vaccines, adjuvants (components that stimulate the immune system) are included with the influenza antigens.
  • For example, an adjuvant is used in the Fluad Quad vaccine, recommended for over 65s.
  • Studies suggest adjuvanted influenza vaccines are slightly better than standard egg-based vaccines without adjuvant in older people.
  • Read more:
    Should I get the flu shot if I'm pregnant?

What should I do this year?

  • Influenza vaccines are also recommended in pregnancy to protect both the mother and the baby for the first months of life.
  • Influenza vaccines are widely available, including at GP clinics and pharmacies, while many workplaces have occupational programs.


In older people, a number of vaccines are now recommended: COVID and influenza, as well as one-off courses of pneumococcal and shingles vaccines. In general, most vaccines can be given in the same visit, but talk to your doctor about which ones you need.

Are there side effects?

  • These are expected and reflect the immune system reacting appropriately to the vaccine, and are mostly mild and short-term.
  • People with egg allergies should discuss this with their doctor, but in general, studies suggest they can safely receive any (including egg-based) influenza vaccines.
  • Serious side effects from the influenza vaccine, such as Guillain-Barré syndrome, a neurological complication, are very rare (one case per million people vaccinated).


Allen Cheng receives funding from the National Health and Medical Research Council and the Australian Department of Health and Aged Care. He is a member of the Australian Technical Advisory Group on Immunisation.

Q&M Dental Group recorded growth in both Revenue and Net Profit after tax attributable to parent of S$182.7 million and S$11.5 million respectively for FY2023

Retrieved on: 
Friday, March 1, 2024

Comparing FY2023 with FY2022, share of loss in Aoxin Q & M, decreased by S$0.5 million for the same reason give above.

Key Points: 
  • Comparing FY2023 with FY2022, share of loss in Aoxin Q & M, decreased by S$0.5 million for the same reason give above.
  • This is mainly attributable to operating cash flow before changes in working capital offset by increase on working capital.
  • As at 31 December 2023, Q & M has cash and cash equivalents of S$34.0 million and bank borrowings plus finance leases amounting to S$80.3 million.
  • Net Aset Value attributable to owners of parent is S$99.1 million as at 31 December 2023 compared to S$96.5 million a year ago, an increase of 3%.

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.

Key Points: 
  • ET
    ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.
  • Results to date have demonstrated safety of this therapy and consistent reduction in treated tumors.
  • Cash Position: GeoVax reported cash balances of $6.5 million on December 31, 2023, as compared to $27.6 on December 31, 2022.
  • ET today, February 29, 2024, to review financial results and provide an update on corporate developments.

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024

Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.

Key Points: 
  • Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.
  • Next steps for Cohort A: plan to report top-line data in the fourth quarter of 2024.
  • Revenues for the fourth quarter of 2023 were approximately $12.1 million compared with approximately $1.0 million for the fourth quarter of 2022.
  • Operating expenses: Total operating expenses for the fourth quarter of 2023 were approximately $13.2 million compared with approximately $9.0 million for the fourth quarter of 2022.

Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

Retrieved on: 
Thursday, February 29, 2024

LAWRENCEVILLE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces positive results from a live virus challenge study conducted for IMUNON by the Wistar Institute with IMNN-101 against the SARS-CoV-2 variant XBB.1.5. This study was conducted using the clinical vector that IMUNON intends to bring into its Phase 1 study during the second quarter and showed IMNN-101 immunogenicity and protective activity in a live viral mouse challenge.

Key Points: 
  • The SARS-CoV-2 XBB.1.5 variant was declared as the variant of concern for the 2023-2024 vaccine by the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee.
  • IMUNON has reported that intramuscular administration of a single dose of IMNN-101 in mice produced IgG neutralizing antibody and T-cell responses.
  • Challenging the mice with live virus 21 days after the second vaccination showed complete protection.
  • Protection in non-human primates was greater than 95%, which is comparable to mRNA.

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

Retrieved on: 
Thursday, February 22, 2024

LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer” by Subeena Sood, Majed M. Matar, et. Al. [https://doi.org.10.1016/j.vaccine.2024.01.065] has been published in the peer-reviewed journal Vaccine, by Elsevier. The article is available at https://authors.elsevier.com/sd/article/S0264-410X(24)00077-X.

Key Points: 
  • [ https://doi.org.10.1016/j.vaccine.2024.01.065 ] has been published in the peer-reviewed journal Vaccine, by Elsevier.
  • The study described in the article used IMUNON’s proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both alone and in combination.
  • DNA formulated with PlaCCine resulted in a DNA vaccine product that was stable for up to one year at 4°C.
  • Dr. Corinne Le Goff, president and chief executive officer of IMUNON, said, “The publication of this manuscript in the prestigious peer-reviewed journal Vaccine adds to the growing body of preclinical data confirming the efficacy and desirable features of our PlaCCine vaccine modality.

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Retrieved on: 
Monday, March 4, 2024

Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.
  • The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents:
    Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2.
  • Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5.
  • Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6.

Global Respiratory Infection Diagnostic Market Research Report 2024-2028 with Executive and Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels

Key Points: 

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels
5.39 Tempus Announces COVID-19 Testing, Data Initiative
5.42 Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
5.43 Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel

Global H3N2 infection Drug Pipeline Landscape Report 2024: Insights on 15+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.
  • A detailed picture of the H3N2 infection pipeline landscape is provided which includes the disease overview and H3N2 infection treatment guidelines.
  • The assessment part of the report embraces, in depth H3N2 infection commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their H3N2 infection drug candidates in the most advanced stage, i.e.

Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts, Strategies and Trends, Forecasts and Executive Guides & Customization - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024

5.2.3 Infectious Disease is Declining But..

Key Points: 
  • 5.2.3 Infectious Disease is Declining But..
    5.2.5 Economic Growth improves Living Standards.
  • 5.3.3 Syndrome Testing Moving to Big Instruments?
  • 5.4.6 Syndromics drives POCT adoption.
  • 5.4.7 A Big Future for PCR?